Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

• Hauptverfasser: Xavier J. H. Pepin (VerfasserIn), Scott M. Hynes (VerfasserIn), Hamim Zahir (VerfasserIn), Deborah Walker (VerfasserIn), Lois Q. Semmens (VerfasserIn), Sandra Suarez‐Sharp (VerfasserIn)
• Format: Buch
• Veröffentlicht: Wiley, 2024-10-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Omaveloxolone is a nuclear factor (erythroid‐derived 2)‐like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an empty stomach. The effect of the US...